鴉片類藥物市場規模、佔有率和成長分析：按處方鴉片類藥物、非處方鴉片類藥物、濫用預防製劑、鴉片類藥物成癮治療和地區分類——2026-2033年行業預測

2024 年全球鴉片類藥物市場價值 12 億美元，預計到 2025 年將成長至 12.5 億美元，到 2033 年將成長至 17.7 億美元，在預測期（2026-2033 年）內複合年成長率為 4.4%。

全球鴉片類藥物市場的主要驅動力是臨床上對有效緩解急性和慢性疾病疼痛的需求，同時受到製藥業創新和法規環境變化的影響。市場最初以處方鎮痛藥為主，由於積極的市場行銷和寬鬆的處方標準而迅速成長。然而，隨後監管的收緊導致非法藥物（包括合成鴉片類藥物）的使用增加。目前的市場動態主要受監管和公共衛生措施的影響，推動了諸如濫用預防配方和非鴉片類替代藥物等創新。隨著處方鴉片類藥物短缺的加劇，合成鴉片類藥物的販運也日益猖獗，導致過量用藥率上升，對成癮治療的需求增加。此外，人工智慧透過分析各種資料來源，加強濫用監測和偵測，促進預防性干預措施的實施，從而提高了市場效率。

全球鴉片類藥物市場成長要素

慢性疼痛患者人數的不斷增加，顯著推高了對有效疼痛管理方案（尤其是鴉片類藥物）的需求。當其他治療方法無效或無法使用時，醫療專業人員通常會依賴鴉片類藥物來治療中度至重度疼痛，這導致處方量和藥房庫存量持續成長。此外，患者尋求緩解症狀，臨床醫生致力於提高患者的生活品質，這也使得對這些藥物的依賴性不斷增強。這種持續的臨床需求正促使製藥公司不斷創新並拓展其鴉片類藥物產品線，進一步推動全球鴉片類藥物市場的穩定成長。

全球鴉片類藥物市場的限制因素

全球鴉片類藥物市場面臨許多限制因素，阻礙了市場成長。嚴格的法律規範和全面的處方監測計劃限制了鴉片類藥物的處方使用。日益嚴格的監管迫使醫療服務提供者更加謹慎，加強病患評估流程，並盡可能選擇非鴉片類藥物療法，導致鴉片類藥物的使用率下降。此外，對風險管理策略和上市後監測要求的增加也使藥物研發過程更加複雜，延長了產品上市時間，導致一些生產商在拓展鴉片類藥物產品線方面猶豫不決。這些監管挑戰疊加在一起，限制了產品的供應，降低了處方頻率，並最終減緩了整體市場成長。

全球鴉片類藥物市場趨勢

隨著業界轉向旨在最大限度減少對傳統鴉片類藥物依賴的替代性疼痛管理策略，全球鴉片類藥物市場正經歷重大變革。除了聯合治療和非鴉片類藥物外，包含生理和行為健康干預措施的多方面疼痛管理方案的開發和整合也顯著增加。這項轉變的主要驅動力是保險公司和醫療保健專業人員對安全性、改善病患功能和提升長期復原效果的共同關注。製藥公司正透過豐富產品系列、投資輔助鎮痛藥以及加強與專家的合作來應對這一變化，以確保這些綜合疼痛管理方案在各種醫療保健機構中得到廣泛應用並獲得保險覆蓋。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球鴉片類藥物市場規模：依處方鴉片類藥物類型分類

• 短效鴉片類藥物
• 長效鴉片類藥物

全球鴉片類藥物市場規模：依非處方鴉片類藥物分類

• 複合產品
  • 對乙醯胺酚/鴉片類組合藥物
  • Ibuprofen和鴉片類藥物
• 單藥療法產品
  • 可待因
  • 二氫可待因

全球鴉片類藥物市場規模：依濫用預防製劑分類

• 用於疼痛管理
• 防止用於非治療目的

全球鴉片類藥物市場規模：按鴉片類藥物成癮治療方法

• Buprenornhine製劑
• 納曲酮製劑

全球鴉片類藥物市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Purdue Pharma
• Mallinckrodt Pharmaceuticals
• Johnson & Johnson
• Teva Pharmaceutical Industries
• Endo International
• Amgen
• Hikma Pharmaceuticals
• AcelRx Pharmaceuticals
• Grunenthal
• Sorrento Therapeutics
• Cara Therapeutics
• Collegium Pharmaceutical
• Indivior
• AbbVie
• Takeda Pharmaceuticals
• Astellas Pharma
• Sanofi
• Pfizer
• Gilead Sciences
• Horizon Therapeutics

結論與建議

Global Opioids Market size was valued at USD 1.2 Billion in 2024 and is poised to grow from USD 1.25 Billion in 2025 to USD 1.77 Billion by 2033, growing at a CAGR of 4.4% during the forecast period (2026-2033).

The global opioids market is primarily driven by the clinical need for effective pain management in both acute and chronic conditions, influenced by pharmaceutical innovation and evolving regulatory environments. Initially focused on prescription analgesics, market growth surged due to aggressive marketing and relaxed prescribing norms, but tighter regulations have since led to a rise in the use of illicit substances, including synthetic opioids. Current market dynamics are significantly shaped by regulatory and public health responses, spurring innovation, including abuse-deterrent formulations and non-opioid alternatives. The increasing shortage of prescription opioids has intensified the trafficking of synthetic variants, leading to higher overdose rates and growing demand for addiction treatment. Moreover, AI is enhancing surveillance and detection of misuse by analyzing diverse data sources, facilitating proactive interventions and improving market efficiency.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Opioids market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Opioids Market Segments Analysis

Global opioids market is segmented by prescription opioids, over-the-counter opioids, abuse deterrent formulations, opioid dependency therapies and region. Based on prescription opioids, the market is segmented into Short-acting Opioids and Long-acting Opioids. Based on over-the-counter opioids, the market is segmented into Combination Products and Single Agent Products. Based on abuse deterrent formulations, the market is segmented into Intended for Pain Management and Non-therapeutic Use Prevention. Based on opioid dependency therapies, the market is segmented into Buprenorphine Products and Naltrexone Products. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Opioids Market

The rising prevalence of individuals suffering from chronic pain has significantly boosted the demand for effective pain management solutions, particularly opioids. Healthcare professionals often turn to opioids for treating moderate to severe pain when other treatment options fall short or are not readily available, thereby strengthening prescribing trends and pharmacy inventories. Furthermore, patients advocate for relief from their symptoms, while clinicians strive to enhance quality of life, ensuring ongoing reliance on these medications. This continual clinical necessity encourages pharmaceutical companies to innovate and expand their opioid offerings, further fueling consistent growth in the global opioids market.

Restraints in the Global Opioids Market

The global opioids market faces significant restraints due to stringent regulatory oversight and thorough prescription monitoring programs that restrict the prescribing of opioids, hindering market expansion. Increased regulatory scrutiny drives healthcare providers to exercise greater caution, enhance patient assessment protocols, and opt for non-opioid therapies whenever possible, resulting in diminished initiation of opioid treatments. Furthermore, the demands for risk management strategies and post-marketing surveillance complicate the development process and extend the time required for product introduction, discouraging some manufacturers from expanding their opioid offerings. Collectively, these regulatory challenges limit product availability and reduce prescribing frequency, ultimately slowing the market's overall growth.

Market Trends of the Global Opioids Market

The Global Opioids market is witnessing a significant transformation as the industry pivots towards alternative pain management strategies aimed at minimizing dependence on traditional opioid therapies. There is a marked increase in the development and integration of multimodal pain management regimens that encompass combination therapies and non-opioid pharmacologics, alongside physical and behavioral health interventions. This shift is largely driven by a collective focus from payers and healthcare providers on safety, enhanced patient functionality, and improved long-term recovery outcomes. Pharmaceutical manufacturers are responding by diversifying their portfolios, investing in adjunctive pain agents, and fostering collaborations with specialty clinicians to ensure broader adoption and reimbursement for these comprehensive pain management solutions across various care environments.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Opioids Market Size by Prescription Opioids & CAGR (2026-2033)

• Market Overview
• Short-acting Opioids
• Long-acting Opioids

Global Opioids Market Size by Over-the-Counter Opioids & CAGR (2026-2033)

• Market Overview
• Combination Products
  • Acetaminophen & Opioids
  • Ibuprofen & Opioids
• Single Agent Products
  • Codeine
  • Dihydrocodeine

Global Opioids Market Size by Abuse Deterrent Formulations & CAGR (2026-2033)

• Market Overview
• Intended for Pain Management
• Non-therapeutic Use Prevention

Global Opioids Market Size by Opioid Dependency Therapies & CAGR (2026-2033)

• Market Overview
• Buprenorphine Products
• Naltrexone Products

Global Opioids Market Size & CAGR (2026-2033)

• North America (Prescription Opioids, Over-the-Counter Opioids, Abuse Deterrent Formulations, Opioid Dependency Therapies)
  • US
  • Canada
• Europe (Prescription Opioids, Over-the-Counter Opioids, Abuse Deterrent Formulations, Opioid Dependency Therapies)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Prescription Opioids, Over-the-Counter Opioids, Abuse Deterrent Formulations, Opioid Dependency Therapies)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Prescription Opioids, Over-the-Counter Opioids, Abuse Deterrent Formulations, Opioid Dependency Therapies)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Prescription Opioids, Over-the-Counter Opioids, Abuse Deterrent Formulations, Opioid Dependency Therapies)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Purdue Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endo International
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AcelRx Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grunenthal
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sorrento Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cara Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Collegium Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Indivior
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations